UPF
9.9.2021 17:53:11 CEST | Business Wire | Press release
A wide range of challenges stand in the way of building a stable and relatively peaceful global order for the 21st Century. Recent events related to the U.S. withdrawal from Afghanistan underscore this fact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005818/en/
Of critical importance to the geopolitical dynamics of our time is the ongoing crisis on the Korean Peninsula, which impacts East Asia and the rest of the world. While efforts toward peace have prevented another war in Northeast Asia, the potential for conflict still remains and would involve the U.S., China, Russia, and Japan. It is time for a new strategy to move toward reconciliation and cooperation on the Korean Peninsula.
Who: Think Tank 2022 Rally of Hope online is sponsored by the Universal Peace Federation (upf.org)
When: Sunday, September 12, 2021, 2:30 a.m. CET, Europe & Middle East (Live broadcast from South Korea) or Replay/Highlights: September 12, 2021, 6:00 PM CET
Where : Join the Live Event September 12th, at 02:30 AM (CET)
through this link: https://www.peacelink.live/online/
Join the Highlight Event September 12th, at 06:00 PM (CET)
through Zoom link: http://www.zoom.rallyofhope.eu/
or Live Facebook: http://www.facebook.rallyofhope.eu/
What: Inaugurated in 2020, the Rally of Hope is a series of live-streamed online productions using advanced augmented reality technology to connect millions of global viewers. Featuring prominent world leaders and captivating entertainment, the Rally of Hope is uplifting, actionable and faith-based.
Why: This new and unique program empowers the ordinary citizen who seeks meaningful change in their personal life, family, community, and even globally, by participating in a movement which transcends political, religious, racial, and ideological boundaries.
Previous Rallies of Hope have provided a platform for top experts to speak about the complex issues facing our planet, including: climate change, geopolitical hotspots, challenges of the coronavirus pandemic, honoring veterans of the Korean War on its 70th anniversary, the role of faith in peacebuilding, and much more.
The theme of the Think Tank 2022 Rally of Hope is “Steps Toward Peace in Asia: Focus on Reconciliation and Cooperation on the Korean Peninsula.” Although the Armistice Agreement brought an end to the hostilities, the Korean Peninsula continues to be a “storm center” for peace and security in the region. World leaders will speak about the risks and opportunities of resolving issues on the Korean Peninsula and steps toward peace in Asia.
Keynote Speakers : Kingdom of Cambodia Prime Minister Hun Sen , European Commission President
José Manuel Barroso (2004-2014), Republic of the Philippines President Gloria Macapagal Arroyo (2000-2010), Republic of India Prime Minister H.D. Deve Gowda (1996-1997), Trinidad and Tobago President Anthony Thomas Aquinas Carmona (2013-2018), and Republic of Serbia President Nataša Mićić (2002-2004). UPF Co-Founder Hak Ja Han Moon will offer a special message of hope in her Founder’s Address .
Find out more about the Rally of Hope & Think Tank 2022 here: https://www.rallyofhope.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005818/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom